News >

Advances Continue With Targeted Agents in ALK+ NSCLC

Caroline Seymour
Published: Friday, Apr 20, 2018

Paul K. Paik, MD

Paul K. Paik, MD
Alectinib (Alecensa) is the preferred frontline treatment for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), but the potential FDA approval of lorlatinib may shift the landscape once again. The problem, says Paul K. Paik, MD, is that physicians are unable to pinpoint exactly how.

In February 2018, the FDA granted a priority review for lorlatinib for use in patients with ALK-positive metastatic NSCLC who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs). Phase II data submitted by Pfizer showed an overall response rate (ORR) of 69% in ALK-positive patients who had received crizotinib (Xalkori), then the frontline standard of care, with or without chemotherapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x